463 patents
Page 10 of 24
Utility
Methods for treating breast and other cancers by targeting argininosuccinate synthetase 1-deficiency
26 Apr 22
Autophagy is the principal catabolic response to nutrient starvation.
David K. Ann, Yun-Ru Chen, Fuming Qiu
Filed: 1 Apr 16
Utility
Development of masked therapeutic antibodies to limit off-target effects
26 Apr 22
In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof.
John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
Filed: 2 Jul 19
Utility
Berbamine Derivatives and Methods of Use Thereof
21 Apr 22
Provided herein are, inter alia, methods of treating cancer using compounds of the invention.
David HORNE, Wendong HUANG, Jun XIE, Binfeng ZHANG, Senlin XU
Filed: 17 Jan 20
Utility
Complementary Rna Linked Bispecific T-cell Engaging Antibodies
21 Apr 22
The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides.
John E. Shively, Lin Li, Maciej Kujawski, Piotr Swiderski
Filed: 15 Oct 21
Utility
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
19 Apr 22
Provided herein are adeno-associated virus (AAV) compositions that can restore F8 gene function in a cell without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease.
Saswati Chatterjee, Laura Jane Smith, Jeff Lynn Ellsworth, Hillard Rubin, Jason Boke Wright, James Anthony McSwiggen
Filed: 19 Feb 19
Utility
5-bromo-indirubins
19 Apr 22
Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
Filed: 13 Feb 20
Utility
Fc Receptor-ACE2 Conjugates and Use Thereof
24 Mar 22
Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2).
John C. WILLIAMS, Miso PARK
Filed: 17 Sep 21
Utility
Chimeric immunoreceptor useful in treating human cancers
22 Mar 22
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain.
Michael Jensen
Filed: 20 Dec 19
Utility
Tumor-selective CTLA-4 antagonists
22 Mar 22
Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease.
John C. Williams, Ulrich Rodeck, Kurt Jenkins
Filed: 3 Sep 19
Utility
Bi Specific Aptamer
10 Mar 22
Provided are aptamers and aptamer compositions and particularly, although not exclusively, to a bi-specific aptamer capable of binding a tumor cell antigen and an immune cell surface protein.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 29 Nov 21
Utility
Compositions and Methods for Treating Autoimmune Diseases
10 Mar 22
Provided herein are, inter alia, anti-CD6 antibody-growth factor complexes including an anti-CD6 antibody portion bound to a growth factor protein (e.g., EGF) through a linker, which may be cleavable by a protease (e.g., diabetic microenvironment specific protease).
Jose Enrique Montero CASIMIRO, Bart Otto ROEP, John Charles WILLIAMS
Filed: 1 Jul 19
Utility
Activatable Masked ANTI-CTLA4 Binding Proteins
10 Mar 22
The invention provides activatable masked anti-CTLA4 binding proteins (e.g., antibodies, bispecific antibodies, and chimeric receptors) and their use in treating and preventing cancer, as well as compositions and kits comprising the activatable masked anti-CTLA4 binding proteins.
John C. Williams, Margaret Karow
Filed: 26 Dec 19
Utility
Methods of quantifying N
8 Mar 22
Methods of quantifying N2-carboxyethyl-2′-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer.
Samuel Rahbar, Timothy W. Synold, John Termini, Daniel Tamae, Gerald Wuenschell
Filed: 29 Dec 17
Utility
Markers of breast cancer and methods for the use thereof
8 Mar 22
In accordance with the present invention, the single gene SERPINA1 has been identified as a significant predictor of survival in ER+ and ER+/HER2+ breast cancer patients.
Shiuan Chen, Hei Jason Chan
Filed: 19 Jan 16
Utility
Use of Endogenous Viral Vaccine In Chimeric Antigen Receptor T Cell Therapy
3 Mar 22
Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein).
John C. WILLIAMS, Christine BROWN, Don J. DIAMOND
Filed: 2 Sep 21
Utility
Txnip-trx Complex Inhibitors and Methods of Using the Same
3 Mar 22
Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.
Rama Natarajan, Feng Miao, Nagarajan Vaidehi, Supriyo Bhattacharya
Filed: 15 Apr 21
Utility
Anti-cancer RNA aptamers
1 Mar 22
Provided herein, inter alia, are compounds capable of binding HSP70 (e.g. mHSP70) on a cell and internalizing into said cell.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 18 Dec 19
Utility
Methods and compositions for measuring beta cell death
1 Mar 22
Provided herein are, inter alia, nucleic acids, methods, and kits for detecting unmethylated DNA in body fluid sample of a subject.
Kevin Ferreri, Mohamed I. Husseiny Elsayed
Filed: 8 Jul 19
Utility
Baff-r Bispecific T-cell Engager Antibody
24 Feb 22
Provided herein are recombinant proteins (e.g., a bispecific antibody) capable of binding BAFF-R.
Hong QIN, Larry W. KWAK
Filed: 19 Dec 19
Utility
IL-6 Signaling and Breast Cancer
24 Feb 22
The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.
Peter P. Lee
Filed: 26 Oct 21